Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 9/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18525926 | 1.00 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL20643823 | 0.91 | EPHX1 (0.44) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL19352948 | 0.91 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL21790405 | 0.88 | EPHX1 (0.42) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL19242564 | 0.86 | TSHR (0.36) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL18482260 | 0.86 | EPHX1 (0.44) | EPHX1TSHRTHRBALDH1A1PPARA | |
| SCHEMBL28182999 | 0.86 | EPHX1 (0.44) | EPHX1TSHRTHRBALDH1A1PPARA | |
| SCHEMBL20869918 | 0.85 | DNM1 (0.42) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL24091302 | 0.85 | DNM1 (0.42) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL24927622 | 0.85 | EPHX1 (0.50) | EPHX1TSHRTHRBALDH1A1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210363147-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | EPHX1 848/4885TSHR 4648/4885THRB 3647/4885 |
| US-20210363147-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | EPHX1 858/4885TSHR 4632/4885THRB 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.